GP和NP方案治疗晚期非小细胞肺癌的随机对照临床研究

Riandomzed clinical navelbine plus cisplatin versus gemcitabine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer

目的比较吉西他滨联合顺铂(GP方案)与长春瑞滨联合顺铂(NP方案)治疗晚期NSCLC的近期疗效和毒性作用。方法105例初治晚期NSCLC患者随机分为GP组和NP组,GP组53例,NP组52例。化疗2周期后对两组的临床疗效和毒性反应进行评价。结果GP组有效率为41.5%,NP组为36.5%,两组间比较差异无统计学意义(P>0.05)。GP组不良反应以血小板降低为主,NP组以静脉炎为主,均可耐受。结论吉西他滨或长春瑞滨联合顺铂治疗晚期NSCLC具有较好的耐受性和临床疗效,不良反应有所不同,但都可以耐受。

Objective Evaluate the efficacy and toxicity of gemcitabine or navelbine combined cisplatin with for patients with advanced NSCLC. Methods One hndred five advanced NSCLC patients were randomly divided into 2 groups, 53 in GP group and 52 in NP group. Results Patients＇ characteristics were similar between the two groups. The overall response rate was 41.5% in the GP group and 36.5% in the NP group. There was no statistically significant difference in response rate between the two groups （P 〉0. 05）. The major cytotoxicity was thrombocytopenia in the GP group and phlebitis in the NP group. Conclusion Both GP and NP regimens are effective for advanced NSCLC and have no significant difference. The side effects of the two regimens are different but all adverse reactions are tolerable.